CAMBRIDGE, U.K. and LILLE, FRANCE--(MARKET WIRE)--Jul 26, 2007 -- Pathogen Removal and Diagnostic Technologies Inc. (“PRDT”), a joint-venture between ProMetic Life Sciences Inc. (Toronto:PLI.TO - News) (“ProMetic”) and The American Red Cross (“ARC”), along with MacoPharma, PRDT’s co-development, commercial and manufacturing partner, announces that MacoPharma contributed to an Independent Public Inquiry on Contaminated Blood and Blood Products that was held in London, U.K., on July 25, 2007.
